BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31 Suppl 1:104-110. [PMID: 21205146 DOI: 10.1111/j.1478-3231.2010.02396.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Miller AO, Brause BD. Perioperative infection in the patient with rheumatic disease. Curr Rheumatol Rep 2013;15:379. [PMID: 24150870 DOI: 10.1007/s11926-013-0379-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Pendyal A, Gelow JM. Cardiohepatic Interactions. Heart Failure Clinics 2016;12:349-61. [DOI: 10.1016/j.hfc.2016.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol 2013;3:301-12. [PMID: 25755518 DOI: 10.1016/j.jceh.2013.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
4 Aygen B, Demir AM, Gümüş M, Karabay O, Kaymakoğlu S, Köksal AŞ, Köksal İ, Örmeci N, Tabak F. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018;29:259-69. [PMID: 29755010 DOI: 10.5152/tjg.2018.18263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 黄利华, 姚悦萍. HBV感染者化疗时的抗病毒治疗. 世界华人消化杂志 2011; 19(15): 1604-1608 [DOI: 10.11569/wcjd.v19.i15.1604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
8 刘瑶, 孔心涓, 姜英俊, 武军, 李新华, 田字彬. 肿瘤患者化疗时乙型肝炎病毒的再激活及核苷类药物的预防作用. 世界华人消化杂志 2013; 21(11): 1050-1054 [DOI: 10.11569/wcjd.v21.i11.1050] [Reference Citation Analysis]
9 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
10 Delladetsima I, Papatheodoridis GV, Tiniakos DG, Hatzakis A, Tassopoulos NC. Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis. Histopathology 2012;61:881-8. [PMID: 22882633 DOI: 10.1111/j.1365-2559.2012.04294.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, Zhu Y, Ye Y, Huang Y, Fu S, Huang H, Luo Y. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:956-64. [PMID: 31962163 DOI: 10.1016/j.bbmt.2020.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544-553. [PMID: 22099371 DOI: 10.1111/j.1478-3231.2011.02682.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
14 Xu J, Zhu H, Zhao Y, Wang X, Shen Y, Wang W, Xu F. Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett 2012;4:471-6. [PMID: 22970045 DOI: 10.3892/ol.2012.745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017; 23(24): 4317-4323 [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
16 Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol. 2016;13:131-149. [PMID: 26837712 DOI: 10.1038/nrgastro.2015.219] [Cited by in Crossref: 141] [Cited by in F6Publishing: 132] [Article Influence: 28.2] [Reference Citation Analysis]
17 Matsunaga S, Jeremiah SS, Miyakawa K, Kurotaki D, Shizukuishi S, Watashi K, Nishitsuji H, Kimura H, Tamura T, Yamamoto N, Shimotohno K, Wakita T, Ryo A. Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus. iScience 2020;23:100867. [PMID: 32105634 DOI: 10.1016/j.isci.2020.100867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
18 Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
19 Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol. 2012;18:225-228. [PMID: 22893874 DOI: 10.3350/cmh.2012.18.2.225] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
20 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
21 Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations. World J Gastroenterol 2015; 21(6): 1738-1748 [PMID: 25684938 DOI: 10.3748/wjg.v21.i6.1738] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
22 Bestas R, Yalcin K. Clinical and Virological Features of Acute Hepatic Exacerbations in Patients With Chronic Hepatitis B Virus Infection. Cureus 2021;13:e15937. [PMID: 34194888 DOI: 10.7759/cureus.15937] [Reference Citation Analysis]
23 Laurenti L, Autore F, Innocenti I, Vannata B, Piccirillo N, Sorà F, Speziale D, Pompili M, Efremov D, Sica S. Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. Leuk Lymphoma 2015;56:2841-6. [PMID: 25682966 DOI: 10.3109/10428194.2015.1017822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
24 Oketani M, Uto H, Ido A, Tsubouchi H. Management of hepatitis B virus-related acute liver failure. Clin J Gastroenterol 2014;7:19-26. [PMID: 26183504 DOI: 10.1007/s12328-013-0447-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
25 Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
26 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
27 Leung DH, Ahamba DC, Pillai LN, Khan MF, Smith EO, Mahoney DH. Unrecognized hepatitis B in pre-screened children with hematologic and oncologic conditions. Pediatr Blood Cancer 2014;61:865-8. [PMID: 24249385 DOI: 10.1002/pbc.24853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-490. [PMID: 29991894 DOI: 10.20524/aog.2018.0266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Borojevic B, Chauhan A, Patterson S. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Rep 2021;14:e243526. [PMID: 34244190 DOI: 10.1136/bcr-2021-243526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sekar B, Newton PJ, Williams SG, Shaw SM. Should we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation? J Transplant 2013;2013:748578. [PMID: 24307939 DOI: 10.1155/2013/748578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Pompili M, Basso M, Hohaus S, Bosco G, Nosotti L, D’andrea M, Fenu S, Grieco A, Laurenti L, Mirisola C, Pagano L, Rapaccini GL, Sica S, Storti S, Landolfi R. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology 2015;14:168-74. [DOI: 10.1016/s1665-2681(19)30778-1] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
32 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
33 Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood 2016;128:488-96. [PMID: 27235136 DOI: 10.1182/blood-2016-01-635060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
34 Baronciani D, Casale M, De Franceschi L, Graziadei G, Longo F, Origa R, Rigano P, Pinto V, Marchetti M, Gigante A, Forni GL. Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm. Hemasphere 2021;5:e555. [PMID: 33969274 DOI: 10.1097/HS9.0000000000000555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Meng C, Belino C, Pereira L, Pinho A, Sampaio S, Tavares I, Bustorff M, Sarmento A, Pestana M. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrologia (Engl Ed) 2018;38:545-50. [PMID: 29709320 DOI: 10.1016/j.nefro.2018.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
36 Juan J, Feld JJ. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol. 2014;26:395-403. [PMID: 24841230 DOI: 10.1097/bor.0000000000000067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
37 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Chang C, Tsai C, Yan S. Hepatitis B reactivation in patients receiving targeted therapies. Hematology 2017;22:592-8. [DOI: 10.1080/10245332.2017.1321882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
39 Akbar SM, Al-mahtab M, Khan SI, Shrestha A, Tabassum S, Hiasa Y. Current trends in hepatitis B vaccination. Future Virology 2016;11:369-78. [DOI: 10.2217/fvl-2016-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]